• Sept.2008 - DSM and LibraGen sign agreement to co-develop transaminases for production of chiral amines Under the terms of the partnership, LibraGen will use its proprietary enzyme discovery and development to identify new enzymes for efficient conversion of a large spectrum of ketons into optically pure R- and S-amines, and DSM will produce these enzymes at industrial scale using DSM’s fermentation capabilities and proprietary expression platform. Both parties will use these novel biocatalysts for screening activities and the development of biocatalytic processes for third parties.

• June 2008 - Inoveol™ : LibraGen's cosmetics actives are now Ecocert-approved. Actives of the Inoveol™ range developed by LibraGen for the dermocosmetic, have just been approved by Ecocert for their conformity according to the ecological and organics standards.

• 16-17 April 2008 - Meet us at In Cosmetics 2008 - LibraGen will attend the next In Cosmetics event in Amsterdam on April to present its range of dermocosmetics actives Inoveol™. Please contact us at contact@libragen.com to arrange one to one meetings for more information on these exclusive High Technology actives.

• 10-11 April 2008 - BioFine 2008, Freiburg Germany:Meet us at Booth#19 & Conference on 'Competitive Bioprocesses for Speciality Fine Chemicals'

• 10.2007 - LibraGen launches two collections of Specialty Enzymes for Fine Chemistry: Arising from LibraGen’s outstanding expertise in industrial biocatalysis for fine chemistry, two collections of "ready to use" recombinant enzymes for fine chemicals synthesis are made available on the market : Chiralmine™ (transaminases for reductive amination) and MEGAsterases™ (esterases for asymmetric synthesis). These enzymes are available under separate items or kits including Control Reaction Buffers and Reference substrates.

• 07.2007 - LibraGen accelerates its growth and signs a commercial agreement with company UNIPEX for the promotion of its Biocatalysis activity in France.

• 06.2007 - Environmental metagenomics : Innovative resource for Industrial Biocatalysis.

• 04.2007 - LibraGen launches its first family of active products obtained by enzymatic transformation of natural substances.

• 11.2006 - LibraGen's innovation policy awarded for it's industrial success.

• 10.2006 - LibraGen and Sanofi-Aventis sign research partnership to identify new candidate molecules for treatment of infectious diseases and cancer.

• 06.07.2006 - LibraGen extends partnership with Yves ROCHER in the biocatalityc production of dermocosmetic compounds